Poznan

• A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto … Recruiting
  2023-504180-16-00 5 2025-04-07 Advanced Breast Cancer
• A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t … Recruiting
  2024-512496-12-00 5 2025-04-01 Moderate to Severe Plaque Psoriasis
• Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head-to-head COMBO-U … Recruiting
  2023-506452-25-00 4 2025-03-27 Ulcerative colitis
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici … Recruiting
  2024-516219-25-00 5 2025-03-25 psoriatic arthritis
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi … Recruiting
  2023-509070-36-00 5 2025-03-18 Major Depressive Disorder with Insomnia Symptoms
• An open-label extension study with dazukibart for participants with idiopathic inflammatory myopathies (including DM or PM) who have complet … Recruiting
  2024-514648-10-00 5 2025-03-14 Idiopathic Inflammatory Myopathy (including dermatomyositis or polymyo
• KEYMAKER U01 Sub-Study E Signal-finding study to test investigational agents with pembrolizumab in combination with chemotherapy in newly di … Recruiting
  2023-509234-19-00 4 2025-03-03 Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-s
• A clinical study of tulisokibart in people with Crohn’s disease or ulcerative colitis (MK-7240-011) Recruiting
  2024-513533-20-00 5 2025-02-25 Crohn’s Disease or Ulcerative Colitis
• Clinical trial of molnupiravir (MK-4482) in adults who have COVID-19 and are not hospitalized, who are at high risk for serious illness from … Recruiting
  2023-507227-36-00 5 2025-02-21 SARS-CoV-2 (COVID-19) infection
• A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-514281-39-00 5 2025-02-14 Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
• A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-515008-38-00 5 2025-02-14 Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad … Recruiting
  2023-505077-32-00 5 2025-01-28 Locally-advanced or metastatic non-squamous non-small cell lung cancer
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A study to evaluate the efficacy and safety of frexalimab, brivekimig or rilzabrutinib in participants aged 16 to 75 years with primary foca … Recruiting
  2024-511775-15-00 4 2025-01-17 Immune system diseases
• Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and pla … Recruiting
  2023-510338-10-00 5 2025-01-15 Recurrent herpes labialis (RHL)
• A trial to learn how safe Dato-DXd is when given with osimertinib, and how well it works compared to osimertinib alone in people who have ad … Recruiting
  2023-509883-89-00 5 2025-01-09 Epidermal growth factor receptor (EGFR) mutation-positive, locally adv
• ZELA trial: Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developi … Recruiting
  2024-513420-41-00 10 2025-01-09 prematurity in neonates
• Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo … Recruiting
  2023-507560-39-00 5 2025-01-07 Acquired Antithrombin Deficiency (Heparin Resistance)
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
  2024-511188-26-00 5 2024-12-20 Relapsed/refractory multiple myeloma in patients who have received 1 t
• A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting
  2023-508813-18-00 4 2024-12-18 Refractory Focal Onset Epilepsy
• Acalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients with Chronic Lymphocytic Leukaemia and Moderate to Severe Cardia … Recruiting
  2023-510147-37-00 6 2024-12-18 Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairmen

Showing 289–312 of 914 trials